Myovant Sciences Ltd. (MYOV) |
|
20.03 -0.12 (-0.6%)
|
07-02 16:00 |
|
Open: |
20.32 |
Pre. Close: |
20.15 |
|
High:
|
20.4448 |
Low:
|
19.8309 |
|
Volume:
|
561,564 |
Market Cap:
|
1,800M |
|
|
|
|
Myovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for women's health and endocrine diseases. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer. It is also developing MVT-602, an oligopeptide kisspeptin agonist, for the treatment of female infertility as part of assisted reproduction. The company was formerly known as Roivant Endocrinology Ltd. and changed its name to Myovant Sciences Ltd. in May 2016. The company was founded in 2016 and is based in London, the United Kingdom. As of December 27, 2019, Myovant Sciences Ltd. operates as a subsidiary of Sumitovant Biopharma Ltd. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
20.479 - 20.596 |
20.596 - 20.722 |
|
Low:
|
19.506 - 19.634 |
19.634 - 19.773 |
|
Close:
|
19.788 - 20.011 |
20.011 - 20.254 |
|
Technical analysis |
as of: 2020-07-02 4:32:41 PM |
|
Overall:
|
 |
| Stoxline posted a SELL today, same as yesterday. Downward movement continues. |
| Target: |
Six months: 25.77 One year: 30.10 |
| Support: |
Support1: 15.78 Support2: 11.89 |
| Resistance: |
Resistance1: 22.07 Resistance2: 25.77 |
| Pivot: |
18.72  |
| Moving Average: |
MA(5): 20.10  MA(20): 18.25
MA(100): 12.27 MA(250): 10.68 |
| MACD: |
MACD(12,26): 1.60 Signal(9): 1.56 |
| Stochastic oscillator: |
%K(14,3): 70.38 %D(3): 68.76 |
| RSI: |
RSI(14): 63.81 |
| 52-week: |
High: 22.07 Low: 4.14 Change(%): 139.9 |
| Average Vol(K): |
3-Month: 137211 10-Days: 177734 |
|
Price, moving averages and Bollinger Bands |
|
Price and moving averages has closed above its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BULLISH in short-term; and BULLISH in mid-long term.MYOV has closed below upper band by 30.0%. Bollinger Bands are 62.8% wider than normal. The large width of the bands suggest high volatility as compared to MYOV's normal range. The bands have been in this wide range for 5 bars. This is a sign that the current trend might continue. |
|
|
Headline News |
Tue, 30 Jun 2020
What's Myovant Sciences Ltd (MYOV) Stock Outlook? - InvestorsObserver
Tue, 30 Jun 2020
BlackDoctor.org, Evidation Health, Movember, and Myovant Sciences Launch Forward Momentum Coalition to Increase Diversity in Research and Develop New Digital Resources for Men with Prostate Cancer - GlobeNewswire
Tue, 30 Jun 2020
Why Buy stock in Myovant Sciences Ltd. (MYOV)? - Marketing Sentinel
Fri, 26 Jun 2020
Do Analysts Expect Myovant Sciences Ltd (MYOV) Stock to Rise Next Year? - InvestorsObserver
Wed, 24 Jun 2020
Myovant Sciences Ltd. (NYSE:MYOV) Stock is Soaring, Here is Why - The Oracle Dispatch
Wed, 24 Jun 2020
Is Myovant Sciences Ltd (MYOV) Stock a Great Value? - InvestorsObserver
|
Financial Analysis |
| Growth |
 |
| Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing. |
| Profitability |
 |
| Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs. |
| Solvency |
|
| Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry. |
| Efficiency |
n/a |
| Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not. |
| Click here to get more fundamental analysis.
|
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: New York Stock Exchange |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. (M) |
90 |
| Shares Float (M) |
35 |
|
% Held by Insiders
|
59.91 |
|
% Held by Institutions
|
37.60 |
|
Shares Short (K)
|
3,010 |
|
Shares Short P. Month (K)
|
3,190 |
Stock Financials |
|
EPS
|
-3.370 |
|
EPS Est This Year
|
-1.440 |
|
EPS Est Next Year
|
-1.200 |
|
Book Value (p.s.)
|
-1.210 |
|
Profit Margin
|
|
|
Operating Margin
|
|
|
Return on Assets (ttm)
|
-117.8 |
|
Return on Equity (ttm)
|
|
|
Qtrly Rev. Growth
|
|
|
Gross Profit (p.s.)
|
|
|
Sales Per Share
|
|
|
EBITDA (p.s.)
|
-2.906 |
|
Qtrly Earnings Growth
|
|
|
Operating Cash Flow (M)
|
-221 |
|
Levered Free Cash Flow (M)
|
-109 |
Stock Valuations |
|
PE Ratio
|
-5.94 |
|
PEG Ratio
|
|
|
Price to Book value
|
-16.55 |
|
Price to Sales
|
|
|
Price to Cash Flow
|
-8.14 |
Stock Dividends |
|
Dividend
|
|
|
Forward Dividend
|
|
|
Dividend Yield
|
|
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
